Nodality Inc. said Wednesday that it named Kathleen LaPorte as CEO. She has served as Nodality’s chief business officer since July 2014. Nodality, a biotech firm based in South San Francisco, is backed by Kleiner Perkins, TPG Biotech, Maverick, Pfizer and LabCorp.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nodality, Inc. announced today the appointment of Kathleen LaPorte as Chief Executive Officer. Since July 2014, she has served as the company’s Chief Business Officer. Ms. LaPorte has a solid track record of leading life sciences companies with revolutionary technologies to success. Nodality is a privately held life sciences company whose novel multi-parametric flow cytometry platform – Single Cell Network Profiling (SCNP) – reveals complex biology at the single-cell level, providing unique insights to address the most pressing challenges in drug discovery and development.
Michael Goldberg, Executive Chairman of Nodality’s Board of Directors, said, “We are excited that Kathy will step into the CEO role and look forward to continued growth of the Nodality business under her leadership. The business has very promising potential to accelerate pharmaceutical drug development, which will benefit greatly from Kathy’s extensive experience in structuring deals and in growing life science companies.”
Ms. LaPorte said, “I am excited about the opportunity to lead this dynamic organization. Nodality has a strong team that is creating unique value and insight for its customers. The SCNP technology, along with the specialized informatics platform and experience, will allow the company to begin to deliver on the promise of precision medicine and improved drug development.”
Ms. LaPorte brings over 25 years of industry experience to Nodality, with her most recent successes as Venture Partner at New Leaf Venture (NLV) Partners, with a primary focus on sourcing opportunities for the information convergence sector. While at NLV Partners, she led investments in and served on the Boards of companies including ISTA Pharmaceuticals, Pearl Therapeutics, and Prometheus Laboratories. Notable achievements also include being a Founding Partner of NLV, a co-founder of angel investing group Health Tech Capital in the digital health space and a General Partner of the Sprout Group.
Ms. LaPorte received her B.S. degree in biology summa cum laude, Phi Beta Kappa from Yale University and her MBA degree as an Arjay Miller Scholar from Stanford University Graduate School of Business.
About Single Cell Network Profiling
Nodality’s proprietary Single Cell Network Profiling (SCNP) technology, a multiparametric flow cytometry-based platform, provides robust, human cell-based translational models of disease, drug activity and patient responses. SCNP reveals complex biology by characterizing cell signaling networks in millions of cells at the single cell level. It creates competitive advantages in addressing many of the most pressing challenges in drug discovery and development. SCNP technology, coupled with Nodality’s proprietary data analysis and visualization tools, uniquely reveals complex functional biology to inform more effective drug development decisions.
Nodality is a life science company whose technology platform, SCNP, bridges the gap left by traditional R&D approaches. Nodality provides clinically actionable solutions throughout the full discovery and development process, including disease profiling, drug profiling, clinical development, and life cycle management. Nodality’s team has expertise in identifying solutions across a broad therapeutic landscape, with a focus on immunology and oncology, including immuno-oncology. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds. Major investors include Kleiner Perkins, TPG Biotech, Maverick, Pfizer, and LabCorp.